hsa-mir-4517: Hsa-mir-4517 is a microRNA that has been identified in various studies related to obesity, liver diseases, and innate immune responses. It has been found to target candidate genes associated with child obesity [PMC9092671]. In the context of risk-score prediction models, hsa-mir-4517 is one of the selected miRNA signatures [PMC8633443]. In studies comparing patients with obesity and lean patients, hsa-mir-4517 was found to be downregulated in subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) [PMC6102639]. It was hypothesized that hsa-mir-4517 may function as an inhibitor of RhoA and be transferred through exosomes from mature adipocytes to preadipocytes or distant liver tissue cells [PMC6102639]. The downregulation of exosomal hsa-mir-4517 has been associated with the development of obesity and liver diseases [PMC6102639]. Hsa-mir-4517 was also found to be a shared downregulated exosomal miRNA between SAT and VAT, regulating target genes such as RhoA [PMC6102639]. In other studies, hsa-mir-4517 was shown to play a role in innate immune responses by attenuating inflammation and regulating IL-1β production in monocytes stimulated with LPS [PMC9898544]. It may also serve as a potential biomarker and therapeutic target for non-alcoholic fatty liver disease (NAFLD) [PMC9898544]. Additionally, hsa-mir-4517 has been identified as one of the differential miRNAs in asthma patients compared to healthy controls [PMC9898544][PMC8986441].